By Lizzy Smith | Posted - Jul 29th, 2016

 

 

 

 

CLINICAL TRIAL: Quad Therapy Using a Checkpoint Inhibitor with Daratumumab in Relapsed/Refractory Myeloma

Later this month (July 2016), Celgene will be opening a Phase 1/2 study for approximately 406 relapsed/refractory myeloma patients using the following drugs to actively treat disease: Dararatumumab dexamethasone Durvalumab Pomalidomide Eligibility criteria includes:

  • measurable disease as defined by m-protein or serum free light chains
  • must have failed last line of treatment (refractory to last line of treatment).
  • must have achieved at least a minimal response to at least one prior anti-myeloma regimen before relapse
If you have received prior treatment with daratumumab or other anti-CD38 therapy, you are not eligible for this trial.

For more information on this clinical trial, click on the SparkCures box below: SparkCures Clinical Trial: Durvalumab & Daratumumab        

 
Lizzy Smith
About the Author

Lizzy Smith - Lizzy Smith was diagnosed with myeloma in 2012 at age 44. Within days, she left her job, ended her marriage, moved, and entered treatment. "To the extent I'm able, I want to prove that despite life's biggest challenges, it is possible to survive and come out stronger than ever," she says.

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
 

Add a Comment

 

MORE MYELOMA CROWD NEWS


Thanks to our Myeloma Crowd Community sponsors:

.